Large-scale testing (Phase 3)Study completedNCT00485407
What this trial is testing
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
Who this might be right for
Attention Deficit Hyperactivity Disorder
Eli Lilly and Company 377